Abbruzzese, G, Barone, P, Lopiano, L, Stocchi, F. The current evidence for the use of safinamide for the treatment of Parkinson’s disease. Drug Des Devel Ther 2021; 15: 2507–2517.CrossRefGoogle ScholarPubMed

Bianchi, MLE, Riboldazzi, G, Mauri, M, Versino, M. Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson’s disease. Neurol Sci 2019; 40(2): 275–279.CrossRefGoogle Scholar

Borgohain, R, Szasz, J, Stanzione, P, Meshram, C, Bhatt, M, Chirilineau, D, Stocchi, F, Lucini, V, Giuliani, R, Forrest, E, Rice, P, Anand, R. Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord 2014; 29(2): 229–237.CrossRefGoogle ScholarPubMed

Hattori, N, Tsuboi, Y, Yamamoto, A, Sasagawa, Y, Nomoto, M. Efficacy and safety of safinamide as an add-on therapy to l-DOPA for patients with Parkinson’s disease: a randomized, double-blind, placebo-controlled, phase II/III study. Parkinsonism Relat Disord 2020; 75: 17–23.CrossRefGoogle Scholar

Schapira, AH, Fox, SH, Hauser, RA, Jankovic, J, Jost, WH, Kenney, C, Kulisevsky, J, Pahwa, R, Poewe, W, Anand, R. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol 2017; 74(2): 216–224.CrossRefGoogle ScholarPubMed

AHFS Drug information, 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 9 October 2021 via www.medicinescomplete.com.Google Scholar

Alborghetti, M, Nicoletti, F. Different generations of type-B monoamine oxidase inhibitors in Parkinson’s disease: from bench to bedside. Curr Neuropharmacol 2019; 17(9): 861–873.CrossRefGoogle ScholarPubMed

Borgohain, R, Szasz, J, Stanzione, P, Meshram, C, Bhatt, MH, Chirilineau, D, Stocchi, F, Lucini, V, Giuliani, R, Forrest, E, Rice, P, Anand, R. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord 2014; 29(10): 1273–1280.CrossRefGoogle ScholarPubMed

Cattaneo, C, Sardina, M, Bonizzoni, E. Safinamide as add-on therapy to levodopa in mid- to late-stage Parkinson’s disease fluctuating patients: post hoc analyses of Studies 016 and SETTLE. J Parkinsons Dis 2016; 6(1): 165–173.CrossRefGoogle ScholarPubMed

Cattaneo, C, Ferla, RL, Bonizzoni, E, Sardina, M. Long-term effects of safinamide on dyskinesia in mid- to late-stage Parkinson’s disease: a post-hoc analysis. J Parkinsons Dis 2015; 5(3): 475–481.CrossRefGoogle ScholarPubMed

Geroin, C, Di Vico, IA, Squintani, G, Segatti, A, Bovi, T, Tinazzi, M. Effects of safinamide on pain in Parkinson’s disease with motor fluctuations: an exploratory study. J Neural Transm (Vienna) 2020; 127(8): 1143–1152.CrossRefGoogle ScholarPubMed

Giossi, R, Carrara, F, Mazzari, M, Lo, F Re, M Senatore, A Schicchi, F Corrù, VA Fittipaldo, A Pani, I Tramacere, AE Elia, F Scaglione, . Overall efficacy and safety of safinamide in Parkinson’s disease: a systematic review and a meta-analysis. Clin Drug Investig 2021; 41(4): 321–339.CrossRefGoogle ScholarPubMed

Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 9 October 2021 via www.medicinescomplete.com.Google Scholar

Liguori, C, Stefani, A, Ruffini, R, Mercuri, NB, Pierantozzi, M. Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson’s disease patients: a validated questionnaires-controlled study. Parkinsonism Relat Disord 2018; 57: 80–81.CrossRefGoogle ScholarPubMed

Rinaldi, D, Sforza, M, Assogna, F, Savini, C, Salvetti, M, Caltagirone, C, Spalletta, G, Pontieri, FE. Safinamide improves executive functions in fluctuating Parkinson’s disease patients: an exploratory study. J Neural Transm (Vienna) 2021; 128(2): 273–277.CrossRefGoogle ScholarPubMed

Safinamide. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 9 October 2021 via www.medicinescomplete.com.Google Scholar

Stocchi, F, Vacca, L, Grassini, P, Tomino, C, Caminiti, G, Casali, M, D’Antoni, V, Volterrani, M, Torti, M. Overnight switch from rasagiline to safinamide in Parkinson’s disease patients with motor fluctuations: a tolerability and safety study. Eur J Neurol 2021; 28(1): 349–354.CrossRefGoogle ScholarPubMed

Summary of product characteristics – Xadago 50 mg film-coated tablets. Zambon UK Limited (Formerly Profile Pharma Ltd). Electronic Medicines Compendium: Xadago 50 mg film-coated tablets – summary of product characteristics (SmPC) – (emc). Accessed on 9 October 2021 via www.medicines.org.uk.Google Scholar